ODDIFACT
June 23, 2026
Theater 1
Type: Company Presentation
Focus Area:
AI and Digital Health
ODDIFACT is an AI company dedicated to rare diseases. We have built a proprietary system that transforms off-label use of existing drugs into FDA-designated orphan drug programs structured, de-risked, and licensing-ready for pharma partners.
Across 16 programs launched on 4 monoclonal antibodies, with 13 FDA Orphan Drug Designations granted in under 20 months, our competitive edge lies in the cumulative regulatory intelligence our system builds through every FDA submission and IND meeting.
We produce the asset. Pharma partners fund clinical development. We capture upfront payments, milestones, and royalties.
Company HQ City:
Paris
Company HQ State:
France
Company HQ Country:
France
Year Founded:
2024
Lead Product in Development:
Infiximab for Behcet Disease.
Infliximab for Kawasaki disease.
CEO
Pierre-Alexandre TEULIE
Development Phase of Lead Product
NDA Preparation/In Review
When you expect your next catalyst update?
Signing of a deal with one of the largest American manufacturers producing monoclonal antibodies.
FDA IND meetings.
Primary Speaker
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}